Clinical Trials
27 results for Prostate Cancer
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
- Condition: Prostatic Neoplasms
- Study ID: NCT02861573
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
- Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
- Study ID: NCT03678025
Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial
- Condition: Prostate Cancer Metastatic
- Study ID: NCT03655886
High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency
- Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
- Intervention: Drug: Testosterone Enanthate
- Study ID: NCT03522064
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Condition: Prostate Cancer
- Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
- Study ID: NCT03574571
Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Condition: Metastatic Castration-resistant Prostate Cancer
- Study ID: NCT03230734
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Study ID: NCT03874884
A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
- Condition: Metastatic Castration Resistant Prostate Cancer
- Intervention: Drug: Pembrolizumab
- Study ID: NCT04104893
ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Condition: Metastatic Castration-Resistant Prostatic Cancer
- Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
- Study ID: NCT03903835
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
- Condition: Metastatic Castration-resistant Prostate Cancer
- Intervention: Drug: REGN5678, Drug: Cemiplimab
- Study ID: NCT03972657
Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04506567
Early Detection of Prostate Cancer by Liquid Biopsy
- Condition: Prostate Cancer
- Study ID: NCT04556916
Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment
- Condition: Prostate Cancer, Metastatic Prostate Cancer
- Intervention: Combination Product: Standard of Care, Procedure: Minimally Invasive Ablative Therapy (MIAT), Procedure: Radical Therapy (Prostatectomy or Radiotherapy)
- Study ID: NCT03763253
A Phase IIA Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer
- Condition: Prostate Cancer, Stage IV Prostate Cancer
- Study ID: NCT05189457
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
- Condition: Prostatic Neoplasms, Castration-Resistant
- Study ID: NCT04868604
A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT05075577
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04421222
SatisfACtion: A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With Heavily Pre-treated PSMA Positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy.
- Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Study ID: NCT05983198
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT05803941
A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostat
- Condition: Metastatic Castration-resistant Prostate Cancer
- Study ID: NCT06052306
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04946370
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC
- Study ID: NCT05340374
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
- Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC, Prostate Cancer
- Study ID: NCT05383079
A Phase I/II Study of Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
- Condition: Cancer Of Prostate, Prostate Neoplasms
- Study ID: NCT04633252
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hor
- Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- Study ID: NCT06136650
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-b
- Condition: Prostate Cancer Metastatic
- Study ID: NCT06136624
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer
- Condition: Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
- Study ID: NCT06136598